Entrada Therapeutics 8-K Signals Potential Leadership/Comp Changes

TL;DR

**Entrada Therapeutics filed an 8-K hinting at executive changes and compensation updates.**

AI Summary

Entrada Therapeutics, Inc. filed an 8-K on January 3, 2024, reporting events from December 29, 2023. This filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers' and 'Financial Statements and Exhibits'. While the specific details of these changes are not provided in the summary, the filing signals potential shifts in leadership or executive compensation. Investors should pay attention to the full filing to understand the impact of any executive changes or new compensation structures, as these can influence company strategy and financial performance.

Why It Matters

Changes in executive leadership or compensation can significantly impact a company's strategic direction, operational efficiency, and financial health, directly affecting shareholder value.

Risk Assessment

Risk Level: medium — The filing indicates potential changes in leadership or compensation, which can introduce uncertainty or signal strategic shifts, warranting investor attention.

Analyst Insight

A smart investor would review the full 8-K filing to understand the specific details of any executive changes or compensation arrangements, as these could signal future strategic shifts or financial implications for Entrada Therapeutics.

Key Players & Entities

• Entrada Therapeutics, Inc. (company) — the registrant filing the 8-K
• December 29, 2023 (date) — date of the earliest event reported
• January 3, 2024 (date) — date the 8-K was filed
• 001-40969 (other) — Commission File Number
• 81-3983399 (other) — I.R.S. Employer Identification No.

FAQ

Key Financial Figures

• $0.0001 — ge on which registered Common Stock, $0.0001 par value per share TRDA The Nasdaq
• $480,000 — t, Mr. Dowden's salary was increased to $480,000 per year, with a target bonus percentag

Filing Documents

• tm241489d1_8k.htm (8-K) — 27KB
• tm241489d1_ex99-1.htm (EX-99.1) — 8KB
• tm241489d1_ex99-1img001.jpg (GRAPHIC) — 4KB
• tm241489d1_ex99-1img002.jpg (GRAPHIC) — 5KB
• 0001104659-24-000571.txt ( ) — 223KB
• trda-20231229.xsd (EX-101.SCH) — 3KB
• trda-20231229_lab.xml (EX-101.LAB) — 33KB
• trda-20231229_pre.xml (EX-101.PRE) — 22KB
• tm241489d1_8k_htm.xml (XML) — 3KB

02. Departure of Directors or Certain Officers; Election

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 29, 2023, the Board of Directors (the "Board") of Entrada Therapeutics, Inc. (the "Company") appointed Nathan J. Dowden, the Company's Chief Operating Officer, to serve as the Company's President, effective as of January 1, 2024 (the "Effective Date"), in addition to his role as the Company's Chief Operating Officer , replacing Dipal Doshi, the Company's Chief Executive Officer. Mr. Doshi will continue to serve as the Company's Chief Executive Officer from the Effective Date. Mr. Dowden has served as the Company's Chief Operating Officer since November 2019. Prior to joining the Company, from April 2016 to October 2019, Mr. Dowden was Senior Vice President of Corporate Development at Rubius Therapeutics, Inc. ("Rubius"), a publicly traded biopharmaceutical company, where he helped develop and integrate the company's technology, capital formation and communication strategy in support of the organization's evolution from Series A to public listing, and from discovery to clinical stage status. Prior to Rubius, from January 2014 to April 2016, Mr. Dowden served as Managing Director at the Huron Consulting Group Inc. ("Huron"), a publicly traded management consulting firm. He joined Huron after having served as Managing Director of The Frankel Group LLC (acquired by Huron) for 16 years. Mr. Dowden received a B.S. in Finance from the University of Connecticut and an M.B.A. in Finance and Marketing from the University of Chicago Booth School of Business. In connection with Mr. Dowden's promotion to President, Mr. Dowden's salary was increased to $480,000 per year, with a target bonus percentage of 45%, in each case effective as the Effective Date. Mr. Dowden was also granted 60,000 restricted stock units of the Company, effective as of March 1, 2024 (the "Effective Grant Date"), which shall vest over

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release issued by Entrada Therapeutics, Inc. on January 3, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Entrada Therapeutics, Inc. Date: January 3, 2024 By: /s/ Dipal Doshi Dipal Doshi Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR